Journal article
Leukotriene Antagonists as First-Line or Add-on Asthma-Controller Therapy
Abstract
BACKGROUND: Most randomized trials of treatment for asthma study highly selected patients under idealized conditions.
METHODS: We conducted two parallel, multicenter, pragmatic trials to evaluate the real-world effectiveness of a leukotriene-receptor antagonist (LTRA) as compared with either an inhaled glucocorticoid for first-line asthma-controller therapy or a long-acting beta(2)-agonist (LABA) as add-on therapy in patients already receiving …
Authors
Price D; Musgrave SD; Shepstone L; Hillyer EV; Sims EJ; Gilbert RFT; Juniper EF; Ayres JG; Kemp L; Blyth A
Journal
The New England Journal of Medicine, Vol. 364, No. 18, pp. 1695–1707
Publisher
Massachusetts Medical Society
Publication Date
May 5, 2011
DOI
10.1056/nejmoa1010846
ISSN
0028-4793
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Administration, InhalationAdministration, OralAdolescentAdrenergic beta-AgonistsAdultAgedAnti-Asthmatic AgentsAsthmaBronchodilator AgentsDouble-Blind MethodDrug Therapy, CombinationFemaleGlucocorticoidsHumansLeukotriene AntagonistsMaleMiddle AgedQuality of LifeSurveys and QuestionnairesTherapeutic EquivalencyYoung Adult